Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Viridian Therapeutics Inc
(NQ:
VRDN
)
11.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
11.60
Bid (Size)
10.90 (1)
Ask (Size)
13.90 (15)
Prev. Close
11.60
Today's Range
11.60 - 11.60
52wk Range
10.93 - 28.35
Shares Outstanding
9,587,155
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
May 31, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
May 10, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Performance
YTD
-48.10%
-48.10%
1 Month
-25.59%
-25.59%
3 Month
-35.95%
-35.95%
6 Month
-33.90%
-33.90%
1 Year
-58.38%
-58.38%
More News
Read More
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Unveiling 4 Analyst Insights On Viridian Therapeutics
March 20, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Viridian Therapeutics
February 28, 2024
Via
Benzinga
Analyst Ratings for Viridian Therapeutics
December 04, 2023
Via
Benzinga
Where Viridian Therapeutics Stands With Analysts
November 14, 2023
Via
Benzinga
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
April 29, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
March 19, 2024
Via
InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
January 18, 2024
Via
Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
December 18, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
December 18, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.